Citadel Advisors
PMN icon

Citadel Advisors’s ProMIS Neurosciences PMN Stock Holding History

Citadel Advisors’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,803
Closed -$72.3K – 13750
2025
Q3 		$72.3K Buy
6,803
+4,266
+168% +$59.1K ﹤0.01% 12018
2025
Q2 		$31.1K Buy
+2,537
New +$34.6K ﹤0.01% 11970

Other funds holding PMN

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
DEM
Disciplined Equity Management Neptune Beach, Florida $199M AUM 20.69% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's PMN Position: Q4 2025 in Review

Citadel Advisors sold out of ProMIS Neurosciences (PMN) in Q4 2025, closing a stake of 6,803 shares — an estimated $72.3K sold.

Citadel Advisors first reported a position in PMN in Q2 2025 and held it in 2 quarters. The position peaked at $72.3K in Q3 2025. 9 funds tracked by Wall St. Rank hold PMN as of Q4 2025.

  • Citadel Advisors reported no remaining ProMIS Neurosciences position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 6,803 ProMIS Neurosciences shares in Q4 2025, an estimated $72.3K.
  • Citadel Advisors first reported a position in ProMIS Neurosciences in Q2 2025 and held it in 2 quarters.
  • Citadel Advisors's ProMIS Neurosciences position peaked at $72.3K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.